Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial.
Gilles ManceauValérie TalyJulie HenriquesCamille BourreauLaurent MineurJaafar BennounaJérôme DesrameChristophe LouvetCéline LepereMay MabroJoëlle EgreteauOlivier BoucheClaire MulotKatia HormigosKariman ChabaThibault MazardAimery deGramontDewi VernereyThierry AndréPierre Laurent-PuigPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In this first ctDNA assessment of a large series of patients with stage III colon cancer enrolled in phase III trial, post-surgery ctDNA was found in 13.8% of them and was confirmed as an independent prognostic marker.See related commentary by Bent and Kopetz, p. 5449.